Relevance of CYP3A5 Expression on the Clinical Outcome of Patients With Renal Cell Carcinoma

被引:2
|
作者
Matsumoto, Jun [1 ]
Kotera, Yumi [1 ]
Watari, Shogo [2 ]
Takeuchi, Koichi [1 ]
Ueki, Hideo [2 ]
Koyama, Toshihiro [3 ]
Wada, Koichiro [2 ]
Fujiyoshi, Masachika [1 ]
Nasu, Yasutomo [2 ]
Ariyoshi, Noritaka [1 ]
机构
[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Personalized Med & Prevent Healthcare Sci, Okayama, Japan
[2] Okayama Univ, Grad Sch Med Dent Pharmaceut Sci, Dept Urol, Okayama, Japan
[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pharmaceut Biomed, Okayama, Japan
关键词
human; cytochrome P450 CYP3A; renal cell carcinoma treatment outcome; CYTOCHROME-P450; 3A; OVARIAN-CANCER; IDENTIFICATION; RESISTANCE; ISOFORM; LIVER; RAT;
D O I
10.21873/anticanres.15029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: This study aimed to elucidate the detailed characteristics of CYP3A5 expression and the association between CYP3A5 expression and clinical outcomes in patients with renal cell carcinoma (RCC). Patients and Methods: This study retrospectively enrolled 124 Japanese patients with RCC treated at the Okayama University Hospital. The commonest CYP3A5 gene polymorphism, CYP3A5*3, and expression levels of CYP3A5 mRNA and protein in each tissue were examined. Results: Expression of CYP3A5 mRNA and protein in RCC tissues was significantly down-regulated compared to that in adjacent normal tissues. High level of CYP3A5 mRNA expression significantly extended cancer-specific survival (p=0.004) and overall survival (p=0.002). The CYP3A5 mRNA expression level was identified as a significant independent prognostic factor for both cancer-specific survival and overall survival. Conclusion: CYP3A5 could serve as a potential marker for prognostication and treatment planning for patients with RCC.
引用
收藏
页码:2511 / 2521
页数:11
相关论文
共 50 条
  • [31] CYP3A5 Genotype-Phenotype Analysis in the Human Kidney Reveals a Strong Site-Specific Expression of CYP3A5 in the Proximal Tubule in Carriers of the CYP3A5*1 Allele
    Bolbrinker, Juliane
    Seeberg, Stefanie
    Schostak, Martin
    Kempkensteffen, Carsten
    Baelde, Hans
    de Heer, Emile
    Kreutz, Reinhold
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (04) : 639 - 641
  • [32] Study the polymorphism of CYP3A5 and CYP3A4 loci in Iranian population with laryngeal squamous cell carcinoma
    Negar Azarpira
    Mohamad Javad Ashraf
    Bigan Khademi
    Masumeh Darai
    Afsoon Hakimzadeh
    Elham Abedi
    Molecular Biology Reports, 2011, 38 : 5443 - 5448
  • [33] Influence of Combined CYP3A4/CYP3A5 Polymorphisms on Tacrolimus Pharmacokinetic in Tunisian Renal Graft Patients
    Hannachi, I.
    Ben-Fredj, N.
    Chadli, Z.
    Kerkeni, E.
    Ben-Romadhane, H.
    Ben-Fadhel, N.
    Woillard, J. B.
    Boughattas, N. A.
    Aouam, K.
    Chaabane, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2019, 33 : 75 - 75
  • [34] CYP3A5 Polymorphism in Renal Transplantation: A Key to Personalized Immunosuppression
    Pasari, Amit S.
    Balwani, Manish R.
    Gurjar, Prasad
    Bawankule, Charulata
    Bhawane, Amol
    Tolani, Priyanka
    Kashiv, Pranjal
    Dubey, Shubham
    Katekhaye, Vijay M.
    TRANSPLANTATION PROCEEDINGS, 2023, 55 (05) : 1305 - 1309
  • [35] EFFECT OF CYP3A5 GENE POLYMORPHISMS ON THE LEVELS OF TACROLIMUS IN TURKISH RENAL TRANSPLANT PATIENTS
    Ciftci, Hayriye Senturk
    Caliskan, Yasar Kerem
    Guney, Ilter
    Ayna, Tulay Kilicaslan
    Bakkaloglu, Huseyin
    Nane, Ismet
    Aydin, Ali Emin
    Turkmen, Aydin
    Gurtekin, Mehmet
    TISSUE ANTIGENS, 2012, 79 (06): : 495 - 495
  • [36] Pharmacogenetics of Immunosuppressant Polymorphism of CYP3A5 in Renal Transplant Recipients
    Larriba, J.
    Imperiali, N.
    Groppa, R.
    Giordani, C.
    Algranatti, S.
    Redal, M. A.
    TRANSPLANTATION PROCEEDINGS, 2010, 42 (01) : 257 - 259
  • [37] CYP3A5 Polymorphism in Renal Transplantation: A Key To Personalized Medicine
    Gurjar, Prasad
    Pasari, Amit
    Bhawane, Amol
    Tolani, Priyanka
    Kolte, Sanjay
    Katekhaye, Vijay
    Balwani, Manish
    TRANSPLANTATION, 2022, 106 (09) : S160 - S160
  • [38] CYP3A5 Expression: Risk Factor for donor-specific Antibodies after Renal Transplantation
    Krome, Susanne
    TRANSFUSIONSMEDIZIN, 2022, 12 (04) : 200 - 201
  • [39] Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue
    Kivisto, KT
    Bookjans, G
    Fromm, MF
    Griese, EU
    Munzel, P
    Kroemer, HK
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (03) : 387 - 389
  • [40] Population Pharmacokinetic of Tacrolimus in Tunisian Renal Transplant Patients: Influence of CYP34A and CYP3A5 Polymorphisms
    Ben-Fredj, N.
    Hannachi, I.
    Chadli, Z.
    Kerkeni, E.
    Ben-Romadhane, H.
    Ben-Fadhel, N.
    Hammouda, M.
    Boughattas, N. A.
    Chaabane, A.
    Aouam, K.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2019, 33 : 74 - 74